APO RESEARCH · REPORT
Soliris
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
Product & engineering
Understand the product.
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
Selected research
Industry Research
Soliris Industry Research Report 2026
Market perspective
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
Prior to COVID-19, the China market for Soliris was anticipated to grow from US$ 43.15 million in 2020 to US$ 105.67 million by 2026; it is expected to grow at a CAGR of 14.86% during 2021–2026, whereas post-COVID-19 scenario, the market for Soliris is projected to grow from US$ 40.9 million in 2020 (a change by ~-6.4% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ 100.58 million by 2026; it is expected to grow at a CAGR of 14.75% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Soliris market.The classification of Soliris includes Plasma Exchange and Plasma Infusion, and the proportion of Plasma Exchange in 2019 is about 76.36%, and the proportion is in increasing trend from 2013 to 2018.
Soliris is widely used for patients of PNH, aHUS and other. The most proportion of Soliris is used for patients of PNH, and the proportion in 2019 is 66.85%.
Read the full market overview
Report Scope
This report quantifies the global Soliris market in terms of revenue (US$ million) and, where applicable, sales volume (Unit), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Unit) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Soliris Market by Company
Alexion
Soliris Segment by Type
Plasma Exchange
Plasma Infusion
Soliris Segment by Application
PNH
aHUS
Other
Soliris Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Soliris market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Soliris and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Soliris.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Soliris manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Soliris by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Soliris in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Plasma Exchange
- Plasma Infusion
Applications
- PNH
- aHUS
- Other
Companies covered
- Alexion
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Soliris Market Size (2021-2032)
- 2.2.2 Global Soliris Sales (2021-2032)
- 2.2.3 Global Soliris Market Average Price (2021-2032)
- 2.3 Soliris by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Plasma Exchange
- 2.3.3 Plasma Infusion
- 2.4 Soliris by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 PNH
- 2.4.3 aHUS
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Soliris Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Soliris Sales (Unit) of Manufacturers (2021-2026)
- 3.3 Global Soliris Revenue of Manufacturers (2021-2026)
- 3.4 Global Soliris Average Price by Manufacturers (2021-2026)
- 3.5 Global Soliris Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Soliris, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Soliris, Product Type & Application
- 3.8 Global Manufacturers of Soliris, Established Date
- 3.9 Global Soliris Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Alexion
- 4.1.1 Alexion Company Information
- 4.1.2 Alexion Business Overview
- 4.1.3 Alexion Soliris Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Alexion Soliris Product Portfolio
- 4.1.5 Alexion Recent Developments
5 Global Soliris Market Scenario by Region
- 5.1 Global Soliris Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Soliris Sales by Region: 2021-2032
- 5.2.1 Global Soliris Sales by Region: 2021-2026
- 5.2.2 Global Soliris Sales by Region: 2027-2032
- 5.3 Global Soliris Revenue by Region: 2021-2032
- 5.3.1 Global Soliris Revenue by Region: 2021-2026
- 5.3.2 Global Soliris Revenue by Region: 2027-2032
- 5.4 North America Soliris Market Facts & Figures by Country
- 5.4.1 North America Soliris Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Soliris Sales by Country (2021-2032)
- 5.4.3 North America Soliris Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Soliris Market Facts & Figures by Country
- 5.5.1 Europe Soliris Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Soliris Sales by Country (2021-2032)
- 5.5.3 Europe Soliris Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Soliris Market Facts & Figures by Country
- 5.6.1 Asia Pacific Soliris Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Soliris Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Soliris Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Soliris Market Facts & Figures by Country
- 5.7.1 South America Soliris Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Soliris Sales by Country (2021-2032)
- 5.7.3 South America Soliris Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Soliris Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Soliris Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Soliris Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Soliris Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Soliris Sales by Type (2021-2032)
- 6.1.1 Global Soliris Sales by Type (2021-2032) & (Unit)
- 6.1.2 Global Soliris Sales Market Share by Type (2021-2032)
- 6.2 Global Soliris Revenue by Type (2021-2032)
- 6.2.1 Global Soliris Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Soliris Revenue Market Share by Type (2021-2032)
- 6.3 Global Soliris Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Soliris Sales by Application (2021-2032)
- 7.1.1 Global Soliris Sales by Application (2021-2032) & (Unit)
- 7.1.2 Global Soliris Sales Market Share by Application (2021-2032)
- 7.2 Global Soliris Revenue by Application (2021-2032)
- 7.2.1 Global Soliris Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Soliris Revenue Market Share by Application (2021-2032)
- 7.3 Global Soliris Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Soliris Value Chain Analysis
- 8.1.1 Soliris Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Soliris Production Mode & Process
- 8.2 Soliris Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Soliris Distributors
- 8.2.3 Soliris Customers
9 Global Soliris Analyzing Market Dynamics
- 9.1 Soliris Industry Trends
- 9.2 Soliris Industry Drivers
- 9.3 Soliris Industry Opportunities and Challenges
- 9.4 Soliris Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst